A current update on osteonecrosis of the jaw and bisphosphonates abstract. However, you should be aware of this rare but potentially. Osteonecrosis of the jaws is uncommon in patients who have taken oral bisphosphonates for less than three years. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy. Bisphosphonates and osteonecrosis of the jaws australian.
Guidelines for bisphosphonateassociated osteonecrosis of the jaw. It has been speculated that the medication, especially longterm i. I am not suggesting patients stop taking bisphosphonates. Condition bisphosphonates, like alendronate fosamax, description care management tips osteonecrosis of the jaw onj is a condition where the jawbone is exposed and not covered by gums. A current update on osteonecrosis of the jaw and bisphosphonates. Onj is specif ically related to the intravenous form of bps and is. Bisphosphonates have been increasingly recommended for use in patients with osteoporosis, pagets disease, hypercalcemia of malignancy, osteolytic bone metastases, and osteolytic lesions of multiple myeloma. Apr 30, 2018 antiresorptiverelated osteonecrosis of the jaw aronj is a rare but severe side effect of antiresorptive treatment with bisphosphonates or ranklantibody denosumab in patients with malignant diseases or osteoporosis. Although bisphosphonates have a long list of benefits in the treatment of patients with bone metastases, an increasing number of reports describe the complication of bisphosphonaterelated osteonecrosis of the jaw bronj. Their potential to treat other diseases characterized by osteoclastmediated bone resorption has gained attention. Guidelines for bisphosphonateassociated osteonecrosis of the jaw khan aa, sandor gk, dore e, et al. Mri evaluation of bisphosphonaterelated osteonecrosis of. Osteonecrosis of the jaw onj is a wellknown side effect of bisphosphonate bp therapy. Bisphosphonates can also reduce symptoms that pagets disease can cause, such as bone pain, ringing in the ears, dizziness, and numbness or weakness.
Oral use of bisphosphonates for osteonecrosis of the hip has shown some early. The american college of prosthodontists agrees with the recommendation for the term, medicationrelated osteonecrosis of the jaw mronj suggested by the american association of maxillofacial surgeons aaoms to replace the previous, morespecific term, bisphosphonate related. Bisphosphonate complications including osteonecrosis of the. If the inline pdf is not rendering correctly, you can download the pdf file here. In osteoporosis and pagets, the most popular firstline bisphosphonate drugs are alendronate and risedronate. This article aims to provide an overview of bisphosphonates and bronj, to improve the awareness among. Abstractthe literature describes an increasing presence of bisphosphonateinduced. Since 2003 an increasing number of bisphosphonaterelated osteonecrosis of the jaw bronj were reported.
However, their paper includes serious misstatements about bisphosphonates and bone. To evaluate the level of knowledge of dentists from plovdiv, bulgaria, about possible complications of bisphosphonate therapy of patients in dental practice. Oct 09, 2006 several recent reports have described osteonecrosis of the jaws onj associated with the use of bisphosphonates. It is the r2 sidechain that imparts the potency and method of affect on bone cells. Further research is needed to increase knowledge about the underlying. Medicationrelated osteonecrosis of the jaw mon, mronj is progressive death of the jawbone in a person exposed to a medications known to increase the risk of disease, in the absence of a previous radiation treatment. With a better understanding of this side effect, reported incidences for bronj in oral bisphosphonate users have increased in time. Using the populationbased national health insurance claims data of korea from january 1, 2006, through december 3, 2012. The following protocols have been developed by the bc cancer agency department of oral oncology. The patients taking bisphosphonates are at increased risk of developing bisphosphonaterelated osteonecrosis of jaw bronj which is characterised by the presence of an unhealing wound after dental surgery. Risk of jaw osteonecrosis after intravenous bisphosphonates. Using the populationbased national health insurance claims data of korea from january 1, 2006, through december 3, 2012,730 new. Just as an extraction requires bone turnover to heal, dental implants require bone turnover to maintain osseointegration. Guidelines for bisphosphonateassociated osteonecrosis of the.
Oral bisphosphonates alendronate, risedronate and ibandronate, mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract, acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal pain. Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. Oral bisphosphonate related osteonecrosis of the jaw. Jan 01, 2006 the mechanism of bisphosphonates induced osteonecrosis is unclear. Bisphosphonate related osteonecrosis of the jaws bronj in. Pdf bisphosphonateinduced osteonecrosis of the jaw. Pdf bisphosphonate related osteonecrosis of the jaw. Page 1 medicationrelated osteonecrosis of the jaw 2014 update. Pentoxifylline and tocopherol in the treatment of yearly zoledronic. It is recommended that patients should have a dental examination prior to treatment with bisphosphonates. Severe case of osteonecrosis following implant placement in a.
Bisphosphonates and osteonecrosis of the jaw bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. Bisphosphonateassociated osteonecrosis of the jaws. Osteonecrosis of the jaw is a potential complication of nitrogencontaining bisphosphonates. Whilst osteonecrosis of the jaw onj related to the administration of bisphosphonates bps has been investigated for more than 1 decade now, only few data are available. Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer. Bisphosphonate and osteonecrosis of the jaw litwiniuk. Incidence in a homogeneous series of patients with newly diagnosed. Bisphosphonateinduced osteonecrosis of the jaw request pdf. Radicalsurgicaltreatmentofbisphosphonaterelatedosteonecrosisofthejaw. Sep 01, 2009 bisphosphonates have been increasingly recommended for use in patients with osteoporosis, pagets disease, hypercalcemia of malignancy, osteolytic bone metastases, and osteolytic lesions of multiple myeloma. Reports of this complication have increased recently. Bisphosphonaterelated osteonecrosis of the jaw a 3years. Bisphosphonates are a group of drugs used in the treatment of many common diseases, such osteoporosis, bone metastasis, myeloma.
Osteonecrosis of the jaw is a rare complication that has been associated with the use of bisphosphonates. Dental care protocols bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. A doubleblind, randomized, placebocontrolled trial of nearly 2000 older women. Frontiers doseintensity of bisphosphonates and the risk of. May 16, 20 oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. As a result, they are widely used for the prevention and treatment of osteoporosis. Antiresorptiverelated osteonecrosis of the jaw aronj is a rare but severe side effect of antiresorptive treatment with bisphosphonates or ranklantibody denosumab in patients with malignant diseases or osteoporosis.
Oral bisphosphonates spontaneous osteonecrosis of the jaw. Periodontal disease, dentoalveolar surgery, prior trauma, corticosteroid therapy, immunecompromised state predisposing to increased risk of infection, possible vascular insufficiency and an underlying hypercoagulable state secondary to underlying malignancy. Bisphosphonates are effective drugs used to treat important medical conditions affecting the skeleton, such as malignancy and osteoporosis. An overview of other treatment options for osteoporosis in women and men is discussed separately. Medicationrelated osteonecrosis of the jaw wikipedia. Cumulative incidence of bisphosphonate associated osteonecrosis of the jaw in the oncology patient population. Bisphosphonates and osteonecrosis of the jaw annals of. Nov 21, 2006 however, their paper includes serious misstatements about bisphosphonates and bone. However, there have been no headtohead dose comparisons of jaw osteonecrosis after iv bisphosphonates for cancer vs noncancer indications. With a better understanding of this side effect, reported incidences for bronj in oral bisphosphonate users have. Currently their therapeutic use has increased, as also have their adverse effects, one of the most important being the bisphosphonaterelated osteonecrosis of the jaw bronj, a. Bone metastases occur in about 80% of men with advanced prostate cancer, 1 75% of patients with metastatic breast cancer 2 and 30% to 60% of patients with advanced metastatic lung cancer, 3 and are present in 35% of. Bisphosphonates are synthetic analogues of pyrophosphate that. There is little doubt that iv bisphosphonates can cause osteonecrosis of the jaw.
Several recent reports have described osteonecrosis of the jaws onj associated with the use of bisphosphonates. Invasive procedure such as tooth extraction and bone biopsies should be avoided. Bisphosphonaterelated osteonecrosis of the jaw in patients with osteoporosis. Bisphosphonate medications bisphosphonates are a class of medications which include pamidronate aredia. Bisphosphonates for osteopenia in postmenopausal women jama. She reported that in may 2009, she underwent an implant rehabilitation with 8 implants and an immediately loaded fixed prosthesis in the maxilla. The mechanism of bisphosphonatesinduced osteonecrosis is unclear. Bisphosphonates for treatment of osteoporosis expected beneits, potential harms, and drug holidays. Bisphosphonateassociated adverse events springerlink.
Bisphosphonates are recommended in the treatment of osteoporosis and some cancers, in which case they prevent the appearance of bone metastasis. Clinical findings of bisphosphonaterelated osteonecrosis of the jaw bronj bisphosphonaterelated osteonecrosis of the jaw bronj is an area of uncovered bone in the maxillofacial region that did not heal within 8 weeks after identification by health care provider, in a patient who was receiving or had been exposed to bisphosphonate therapy bpt without previous radiation. However, bisphosphonates are under scrutiny because of the risk of bisphosphonaterelated osteonecrosis of the jaw. Iv forms of bisphosphonates are used with some cancer treatments and it raises the risks of developing medication related osteonecrosis of the jaw mronj. There is no test to measure onj risk, but some factors are known to raise this risk in very rare. Pathophysiology of bisphosphonatesassociated osteonecrosis of the jaw r21 pa06501. Endodontic implications of bisphosphonateassociated osteonecrosis of the jaws aae position statement. Bisphosphonaterelated osteonecrosis of the jaws bronj core. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw bronj. The frequency of osteonecrosis of the jaws associated with dental implants is unknown. It is recommended that you have a good dental exam prior to starting these medications. Bisphosphonates inhibit bone resorption with relatively few side effects.
However, several predisposing factors have been identified. John bilezikian asks whether there is a relationship between bisphosphonates and osteonecrosis of th. Bp induced osteonecrosis of maxilla in a patient who was on a low dose oral bp for osteoporosis and the lesion healed. Their role is to inhibit osteoclast function, leading to lower bone resorption. Bisphosphonate complications including osteonecrosis of. Care guidelines are based on expert opinion but clinical decisions are left up to practitioners. Bisphosphonate associated osteonecrosis of the jaw. Frontiers doseintensity of bisphosphonates and the risk. A medline search 1966january 2007 and a search of international pharmaceutical abstracts 1970january 2007 were. Risk of osteonecrosis of the jaw in cancer patients taking. These benefits outweigh the risk of side effects of bisphosphonates, which are minimal. Osteonecrosis of the jaw and the role of bisphosphonates.
Bisphosphonates and osteonecrosis of the jaw request pdf. Dec 20, 2012 clinical findings of bisphosphonaterelated osteonecrosis of the jaw bronj bisphosphonaterelated osteonecrosis of the jaw bronj is an area of uncovered bone in the maxillofacial region that did not heal within 8 weeks after identification by health care provider, in a patient who was receiving or had been exposed to bisphosphonate therapy bpt without previous radiation therapy to the. Bisphosphonates are the most clinically important class of antiresorptive agents available. Borromeo department of dentistry, university of melbourne, australia. Bisphosphonate drug holidays can be considered for patients who have persisted with bisphosphonate therapy for 3 to 5 years and for those at low risk of fracture. Citing the beagle dog study by mashiba and colleagues 2, woo and colleagues state that prolonged use of bisphosphonates may suppress bone turnover to the point that microdamage persists and accumulates, resulting in decreased biomechanical competence. Periodontal disease, dentoalveolar surgery, prior trauma, corticosteroid therapy, immunecompromised state predisposing to increased risk of infection, possible vascular insufficiency and an underlying hypercoagulable state secondary to underlying malignancy have been. Risk factors for bisphosphonate associated jaw osteonecrosis. Whilst osteonecrosis of the jaw onj related to the administration of bisphosphonates bps has been investigated for more than 1 decade now, only few data are available on. This needs to be considered when developing a dental treatment plan and makes preventive dental care very important.
Bisphosphonates bps have been used for the management of bone metabolic diseases. The incidence of bone metastases is high among patients with advanced cancer. Keywords bisphosphonates osteonecrosis of the jaws. Selfhealing lesion of bisphosphonate induced osteonecrosis of. This material may not otherwise be downloaded, copied, printed, stored, transmitted. Bisphosphonaterelated osteonecrosis of the jaw in patients with. Bisphosphonates and osteonecrosis of the jaw bc cancer.
I am simply informing my chiropractic colleagues of one side affect of a very commonly used treatment for osteoporosis. To examine the incidence rates and association between doseintensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among korean osteoporotic patients older than 50 years. Bisphosphonateassociated osteonecrosis of the jaw bonj is a rare but painful condition that can affect quality of life. Biphosphonatesrelated osteonecrosis of the jaw bialozyk. Read download file report abuse imaging of bisphosphonate related osteonecrosis of the jaw aaoms position paper on bisphosphonaterelated osteonecrosis of the jaw 2009 update approved by the board of trustees january 2009 task force on. Nih funding opportunities and notices in the nih guide for grants and contracts.
Osteonecrosis of the jaw associated with bisphosphonates. Rheumatologists treating bone diseases with bisphosphonate need, therefore, to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of. Bisphosphonateassociated osteonecrosis of the jaws baonj is a side effect of treatment with bisphosphonate bp. The earliest report of bisphosphonate associated jaw osteonecrosis occurred after 4 months of treatment. Bisphosphonates and osteonecrosis of the jaw side effect. To the editor the jama insights article on bisphosphonates for postmenopausal osteoporosis commented that no clinical trials have assessed benefit of treatment with bisphosphonates in women with osteopenia. Bisphosphonates are used to treat osteoporosis, osteitis deformans pagets disease of the bone, bone metastasis with or without hypercalcaemia, multiple myeloma, and other conditions involving fragile, breakable bone. Pdf bisphosphonateinduced osteonecrosis of the jaws. Osteonecrosis of the jaw in patients transitioning from. This article is from journal of clinical and experimental dentistry, volume 4. The relationship between osteonecrosis of the jaw and bisphosphonate therapy has been described recently. Nov 21, 2006 woo and colleagues 1 highlight the substantial difference in the risk for osteonecrosis of the jaw between patients with cancer who receive high doses of intravenous bisphosphonates and patients with nonmalignant skeletal disorders who receive considerably lower doses, but their recommendations for managing the disorder do not reflect the difference. Further research is needed to increase knowledge about the underlying mechanisms and risk factors for onj, and about. In this report, we compare the incidence of jaw osteonecrosis among patients with cancer versus patients without cancer who received iv bisphosphonates.
Rheumatologists treating bone diseases with bisphosphonate need, therefore, to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of potential consequences. Woo and colleagues 1 highlight the substantial difference in the risk for osteonecrosis of the jaw between patients with cancer who receive high doses of intravenous bisphosphonates and patients with nonmalignant skeletal disorders who receive considerably lower doses, but their recommendations for managing the disorder do not reflect the difference. Most of the people who have gotten onj while taking bisphosphonates have. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Osteonecrosis of the jaw and atypical subtrochanteric and diaphyseal femur fractures might be related to the use of bisphosphonates in osteoporosis, but they are. Osteonecrosis of the jaw onj is a very rare side effect of bisphosphonates. Pamidronate aredia and zoledronate zometa induced avascular necrosis of the jaws. Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well known complication at maxillofacial units around the world. The frequency of osteonecrosis of the jaws associated with dental implants is. Pdf bisphosphonate associated osteonecrosis of the jaw. Jun 04, 2006 the risk of jaw osteonecrosis increased with duration of exposure to intravenous bisphosphonate, with the median time of exposure until the development of jaw osteonecrosis of 22 to 39 months. A 77yearold patient presented in april 20 asking for a consultation. Background the purpose of this study was to describe the clinical characteristics. This report documents a case of bisphosphonaterelated osteonecrosis of the jaw mronj.
Guidelines for bisphosphonateassociated osteonecrosis of. Effects of bisphosphonates tend to last even after the person stops taking the medicine. The condition is called bisphosphonate related osteonecrosis of the jaw bronj 16, which was changed by the. The aim of this study is to describe the radiological features of bisphosphonate osteonecrosis bon in order to aid its prompt recognition. We present a case of a 77yearold woman with metastatic breast cancer and osteonecrosis of the jaw after a longterm intravenous treatment with bisphosphonate. Osteonecrosis of the jaw is typically associated with trauma to the jaw tooth extraction, history of malignancy andor infections while on bisphosphonate therapy. Osteonecrosis of the jaw do bisphosphonates pose a risk. Bisphosphonate dental care protocol bisphosphonates and osteonecrosis of the jaw. However, the risk of onj for osteoporosis patients taking these types of drugs is very low much lower than the risk of breaking a bone. Oral bisphosphonates as a cause of bisphosphonaterelated bisphosphonaterelated osteonecrosis of the jaws bronj in my patient on oral bisphosphonates. The most important factor is the time of exposure to bisphosphonates. Bisphosphonates may take several months to become fully effective. Severe case of osteonecrosis following implant placement.
1129 14 192 440 339 832 1537 1354 1357 1229 146 544 1252 1098 676 1568 1270 241 1327 75 671 781 80 1382 1252 593 251 103 1187 925 1284 7 701